Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AstroRx · 1 trial · 1 indication
Safety and tolerability assessment will be based on treatment emerged adverse events
| Arm | Type | Description |
|---|---|---|
| AstroRx | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AstroRx | BIOLOGICAL | Astrocytes derived from human embryonic stem cells |
Main Inclusion Criteria: 1. El Escorial criteria for probable or definite ALS 2. Males and and non pregnant females between 18 and 70 years of age 3. Patients with an ALS-FRS-R score of at least 30 with an ALS diagnosis of two years or less 4. No history of active psychiatric disorder. Patients rec...
AstroRx is an investigational cell therapy being developed by NewcelX Ltd. for amyotrophic lateral sclerosis (ALS). It consists of astrocytes derived from human embryonic stem cells and is administered by transplantation. AstroRx has been studied in a single Phase 1 clinical trial conducted in Israel.
AstroRx is being developed as a potential treatment for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. The therapy involves transplantation of astrocytes derived from human embryonic stem cells. It is intended to support motor neurons and slow disease progression, though it remains investigational.
AstroRx is being developed by NewcelX Ltd., a biotechnology company. The company's ticker symbol is NCEL. NewcelX is focused on developing cell-based therapies, with AstroRx as its lead candidate for ALS.
AstroRx is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The trial enrolled 16 patients and was conducted in Israel. AstroRx is not approved by the FDA or any other regulatory agency.
AstroRx has been evaluated in a single completed Phase 1 clinical trial, NCT03482050, titled "A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)." The trial enrolled 16 participants in Israel and was an uncontrolled, non-randomized study.